Hill Rebecca J
Rebecca J Hill, Children's Nutrition Research Centre, Queensland Children's Medical Research Institute, The University of Queensland, Herston, Qld 4029, Australia.
World J Gastroenterol. 2014 Mar 28;20(12):3191-7. doi: 10.3748/wjg.v20.i12.3191.
Growth and nutritional status are important issues in paediatric inflammatory bowel disease (IBD). While linear growth is easy to assess, nutritional status is more complicated, with reports often compromised by the use of simple measures, such as weight and the body mass index, to assess nutritional status rather than more appropriate and sophisticated techniques to measure body composition. This review is an update on what is currently known about nutritional status as determined by body composition in paediatric IBD. Further, this review will focus on the impact of biologics on growth in paediatric IBD. Significant lean mass deficits have been reported in children with IBD compared with controls, and there is evidence these deficits persist over time. Furthermore, data imply that gender differences exist in body composition, both at diagnosis and in response to treatment. With respect to growth improvements following treatment with biologics, there are conflicting data. While some studies report enhancement of growth, others do not. The relationship between disease severity, impaired growth and the requirement for biologics needs to be considered when interpreting these data. However, key features associated with improvements in growth appear to be successful clinical response to treatment, patients in early stages of puberty, and the presence of growth failure at the onset of treatment.
生长和营养状况是小儿炎症性肠病(IBD)中的重要问题。虽然线性生长易于评估,但营养状况更为复杂,报告往往因使用体重和体重指数等简单指标来评估营养状况,而非采用更合适、更精密的技术来测量身体成分而受到影响。本综述是关于小儿IBD中由身体成分所确定的营养状况的现有认知的更新。此外,本综述将聚焦生物制剂对小儿IBD生长的影响。与对照组相比,IBD患儿已报告存在显著的瘦体重不足,且有证据表明这些不足会随着时间持续存在。此外,数据表明在诊断时以及对治疗的反应方面,身体成分存在性别差异。关于生物制剂治疗后的生长改善情况,数据存在矛盾。虽然一些研究报告生长得到增强,但其他研究则不然。在解读这些数据时,需要考虑疾病严重程度、生长受损与生物制剂需求之间的关系。然而,与生长改善相关的关键特征似乎是对治疗的成功临床反应、处于青春期早期的患者以及治疗开始时存在生长衰竭。